Teladoc Health GLP-1 at a glance: Virtual GLP-1 weight management from Teladoc Health, Inc. (NYSE: TDOC), a publicly-traded major mainstream telehealth platform. 12% average weight loss at 12 months. 92% of members continue GLP-1 therapy after 1 year. 98% continue to engage with Teladoc Health after 1 year. Access via insurance + employer + health plan sponsor (the primary distribution channel) with self-pay options available for those not covered. Teladoc Health mobile app on iOS (Apple App Store) and Android (Google Play). 15 published GLP-1 educational articles covering pre-treatment guidance, medication differences, side-effect management, and supportive medical advice. Comprehensive corporate infrastructure: Investor Relations + Newsroom + Careers + Leadership + Trust Center + Accessibility + Compliance. Trustpilot reviews link with published member testimonial (Laura B., >10% body weight loss since July). Best for buyers with insurance, employer, or health-plan-sponsor access to Teladoc Health who want NYSE-listed parent infrastructure + 12-month outcome data + high retention. Skip if you want flat-rate compounded GLP-1 without insurance coordination.
✓ Pick Teladoc Health if
You have insurance, employer, or health plan sponsor access to Teladoc Health; you value NYSE-listed parent (Teladoc Health, Inc., TDOC); you appreciate the 12% avg weight loss at 12 months outcome data; you value the 92% / 1 year GLP-1 continuation and 98% / 1 year engagement retention metrics; you want integrated mobile app (iOS + Android); you value the comprehensive corporate infrastructure; you appreciate the 15 published GLP-1 educational articles; you want a multi-service Teladoc Health platform beyond GLP-1.
✕ Skip Teladoc Health if
You want flat-rate cash-pay compounded GLP-1; you don't have employer or insurance access to Teladoc Health and don't want to navigate self-pay; you want upfront published per-medication GLP-1 prices without an eligibility check; you have GLP-1 contraindications; or you prefer a GLP-1-only specialty clinic over a broader integrated telehealth platform.
Our verdict on Teladoc Health GLP-1
- Best for
- Buyers with insurance, employer, or health-plan-sponsor access to Teladoc Health wanting NYSE-listed parent + 12-month outcome data + high published retention metrics + integrated telehealth platform.
- GLP-1 strengths
- Teladoc Health, Inc. (NYSE: TDOC) publicly-traded major mainstream parent; HQ 155 East 44th Street Suite 1700 New York NY 10017; 12% average weight loss at 12 months published outcome data; 92% of members continue GLP-1 therapy after 1 year retention metric; 98% continue to engage with Teladoc Health after 1 year; insurance + employer + plan-sponsor primary distribution channel; self-pay options for those not covered; mobile app on iOS (Apple App Store) and Android (Google Play); 15 published GLP-1 educational articles covering pre-treatment + medication differences + side effects + nutrition + supportive medical advice + transition-off planning; comprehensive corporate infrastructure (Investor Relations + Newsroom + Careers + Leadership + Trust Center + Accessibility + Compliance); published Trustpilot reviews link; published member testimonial (Laura B., >10% body weight loss since July); multi-service Teladoc Health platform beyond GLP-1 (Primary360 + Mental Health + Chronic Condition Management + Express Care + Dermatology + Sexual Health + Skin Care); country-specific privacy versions (Spanish + International + Japan + Canada); accessibility-conformance commitment.
- GLP-1 drawbacks
- GLP-1 program access typically requires that the member's employer or health plan offer Teladoc Health — direct consumer self-pay path exists but is the secondary route; specific cash-pay GLP-1 pricing surfaces during the eligibility check / self-pay registration flow rather than published upfront; clinical model not optimized for direct-to-consumer compounded GLP-1; no published 365-day money-back GLP-1 warranty.
- GLP-1 pricing
- Access via insurance, employer, or health plan sponsor — out-of-pocket depends on plan benefits. Self-pay options available for those not covered.
- Editor's rating
- 4.4 / 5 — Distinctive positioning: NYSE-listed parent + 12-month outcome data + 92% continuation retention + comprehensive corporate infrastructure.
Start with Teladoc Health today
NYSE: TDOC parent. 12% avg weight loss at 12 mo. 92% continue GLP-1 at 1 yr. 98% continue to engage. Insurance + employer + plan-sponsor + self-pay access.
Visit Teladoc Health's Official Site →The 12% / 92% / 98% outcome data
Teladoc Health publishes three primary GLP-1 outcome metrics: 12% average weight loss at 12 months, 92% of members continue GLP-1 therapy after 1 year, and 98% of members continue to engage with Teladoc Health after 1 year. The combination of magnitude (12%) + durability (92% continuation) + engagement (98%) across a 12-month window is editorially distinctive — many GLP-1 platforms publish either weight-loss magnitude or short-window snapshots, not both magnitude and durability at 12 months.
How access works — insurance, employer, plan sponsor, or self-pay
Per Teladoc Health: "Members may access Teladoc Health's GLP-1 program through their insurance, employer, or health plan sponsor and self-pay options are available for those who do not have access." Teladoc Health's dominant distribution channel is via employers and health plans rather than direct-to-consumer — checking eligibility typically happens through your benefits portal or via the Teladoc Health registration flow at teladochealth.com.
Per Teladoc Health on the eligibility check: "A care option might already be available to you through one of our partners. Check to see if you qualify."
What we verified about Teladoc Health GLP-1
| What we checked | What we found |
|---|---|
| Brand & entity VERIFIED | Teladoc Health, Inc. · © 2026 All rights reserved |
| Domain VERIFIED | teladochealth.com |
| NYSE: TDOC publicly traded VERIFIED | Investor Relations: ir.teladochealth.com |
| Headquarters VERIFIED | 155 East 44th Street, Suite 1700, New York, NY 10017 |
| 12% avg weight loss at 12 months VERIFIED | Published outcome data |
| 92% / 1 year GLP-1 continuation VERIFIED | "92% of members continue GLP-1 therapy after 1 year" |
| 98% / 1 year engagement retention VERIFIED | "98% of members continue to engage with Teladoc Health after 1 year" |
| Insurance + employer + plan-sponsor access VERIFIED | Primary distribution channel |
| Self-pay options VERIFIED | "Self-pay options are available for those who do not have access" |
| Teladoc Health mobile app VERIFIED | iOS (Apple App Store) + Android (Google Play) |
| GLP-1 program landing page VERIFIED | teladochealth.com/individuals/glp-1 |
| 15 published GLP-1 educational articles VERIFIED | Pre-treatment + medication differences + side effects + supportive advice + transition-off |
| Trustpilot reviews link VERIFIED | trustpilot.com/review/teladochealth.com |
| Trustpilot member testimonial VERIFIED | Laura B.: "I've lost over 10% of my body weight since July" |
| Investor Relations VERIFIED | ir.teladochealth.com |
| Newsroom VERIFIED | newsroom.teladochealth.com |
| Careers VERIFIED | careers.teladochealth.com |
| Leadership + Trust Center + Accessibility + Compliance VERIFIED | Comprehensive corporate infrastructure |
| Multi-service Teladoc platform VERIFIED | Primary360 + Mental Health + Chronic Condition Management + Express Care + Dermatology + Sexual Health + Skin Care |
| Legal documentation VERIFIED | Privacy Policy + Terms of Use + Notice of Privacy Practices + country-specific privacy versions (Spanish + International + Japan + Canada) |
| Direct consumer flat-rate GLP-1 price upfront CAUTION | Surfaces during eligibility / self-pay registration flow |
| Compounded GLP-1 path CAUTION | FDA-approved branded GLP-1 only; direct-to-consumer compounded not the primary path |
| 365-day money-back GLP-1 warranty CAUTION | Not published |
All claims verified on teladochealth.com as of June 2026. Teladoc Health's combination of NYSE-listed parent + 12-month outcome data + 92% continuation retention + comprehensive corporate infrastructure is editorially distinctive in consumer telehealth GLP-1.
Are Teladoc Health's GLP-1 medications compounded or FDA-approved?
Teladoc Health coordinates FDA-approved branded GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) through insurance, employer, or self-pay channels. The platform is not a direct-to-consumer compounded GLP-1 distributor.
The 2026 GLP-1 regulatory landscape
The FDA resolved the official semaglutide GLP-1 shortage in early 2025. Teladoc Health's FDA-approved-branded + insurance-coordinated model is structurally insulated from compounded-only supply tightening.
Teladoc Health GLP-1 pros and cons
✓What we like
- NYSE-listed parent Teladoc Health, Inc. (NYSE: TDOC) — publicly traded major mainstream telehealth platform
- HQ 155 East 44th Street Suite 1700 New York NY 10017
- 12% avg weight loss at 12 months published outcome data
- 92% of members continue GLP-1 therapy after 1 year retention metric
- 98% of members continue to engage with Teladoc Health after 1 year
- Insurance + employer + health plan sponsor primary distribution channel
- Self-pay options for those not covered
- Teladoc Health mobile app on iOS (Apple App Store) + Android (Google Play)
- 15 published GLP-1 educational articles: pre-treatment + medication differences + side effects + nutrition + supportive medical advice + transition-off
- Comprehensive corporate infrastructure: Investor Relations + Newsroom + Careers + Leadership + Trust Center + Accessibility + Compliance
- Published Trustpilot reviews link with member testimonial (Laura B., >10% body weight loss since July)
- Multi-service Teladoc Health platform beyond GLP-1: Primary360 + Mental Health + Chronic Condition Management + Express Care + Dermatology + Sexual Health + Skin Care
- Country-specific privacy versions (Spanish + International + Japan + Canada)
- Accessibility-conformance commitment
✕Where Teladoc Health falls short
- GLP-1 program access typically requires employer or health plan offer Teladoc Health — direct consumer self-pay path is secondary
- Specific cash-pay GLP-1 pricing surfaces during eligibility / self-pay registration flow rather than published upfront
- Clinical model not optimized for direct-to-consumer compounded GLP-1
- No published 365-day money-back GLP-1 warranty
- For lowest possible flat-rate cash-pay GLP-1, the platform may not be the best structural fit
Start with Teladoc Health today
NYSE: TDOC. 12% avg weight loss / 12 mo. 92% GLP-1 continuation / 1 yr. 98% engagement / 1 yr. Insurance + employer + plan-sponsor + self-pay access.
Visit Teladoc Health's Official Site →Teladoc Health GLP-1 sign-up & ongoing-care checklists
Before sign-up
- Check insurance + employer + plan-sponsor coverage.
- Verify NYSE: TDOC parent + Trust Center + Compliance.
- Read 15 published GLP-1 educational articles.
- Review the 12% / 92% / 98% outcome data.
- Check Trustpilot reviews.
- Have medical history ready.
- Register at teladochealth.com or via your employer's benefits portal.
After sign-up
- Download Teladoc Health mobile app (iOS or Android).
- Schedule virtual visit with Teladoc Health clinician.
- Receive FDA-approved GLP-1 medication if appropriate.
- Track progress against 12% / 12 mo benchmark.
- Stay engaged — 98% of members continue engagement after 1 year.
- Use Support for ongoing clinical questions.
Canceling Teladoc Health
- Review access type (employer vs self-pay).
- Contact Teladoc Health Support via teladochealth.com/support.
- Notify HR / benefits administrator if applicable.
- Cancel a few days before next billing.
- Request written confirmation.
- Don't dispose of remaining GLP-1 medication immediately.
Teladoc Health GLP-1 frequently asked questions
How much does Teladoc Health's GLP-1 program cost in 2026?
Primarily accessed via insurance, employer, or health plan sponsor. Self-pay options available for those not covered. Pricing surfaces during eligibility / registration flow.
Is Teladoc Health's GLP-1 program legit?
Yes — Teladoc Health, Inc. is publicly traded on NYSE under TDOC. HQ at 155 East 44th Street Suite 1700 NY NY 10017. Comprehensive corporate infrastructure.
What outcome data does Teladoc Health publish for GLP-1?
12% average weight loss at 12 months. 92% of members continue GLP-1 therapy after 1 year. 98% continue to engage with Teladoc Health after 1 year. Plus published Trustpilot testimonial from Laura B.: ">10% body weight loss since July."
How does Teladoc Health's GLP-1 program work?
Access via insurance, employer, or health plan sponsor (primary route) or self-pay (secondary). Members use the Teladoc Health mobile app for ongoing video visits, messaging, and care coordination.
What GLP-1 medications does Teladoc Health support?
FDA-approved branded GLP-1 including Wegovy, Ozempic, Zepbound, and Mounjaro. Specific availability depends on insurance plan benefits.
Does Teladoc Health work with my insurance?
Primary distribution channel is insurance + employer + health plan sponsor. Check eligibility at teladochealth.com or via your employer's benefits portal.
What does the Teladoc Health mobile app include?
iOS (Apple App Store) + Android (Google Play). Supports virtual visits, care team messaging, prescription management, and ongoing care coordination across Teladoc Health's full service portfolio.
What GLP-1 educational content does Teladoc Health publish?
15 articles covering pre-treatment guidance, medication differences (Semaglutide vs Tirzepatide), side-effect management, nutritional support, supportive medical advice during the GLP-1 journey, and transition-off planning.
How do I cancel Teladoc Health?
Contact Teladoc Health Support at teladochealth.com/support. Members with insurance-coordinated access should also notify HR or benefits administrator.
Are Teladoc Health's GLP-1 medications compounded or FDA-approved?
FDA-approved branded. Teladoc Health coordinates FDA-approved branded GLP-1 (Wegovy, Ozempic, Zepbound, Mounjaro) through insurance, employer, or self-pay channels — not direct-to-consumer compounded GLP-1.
Honest verdict — should you choose Teladoc Health?
Teladoc Health earns its 4.4/5 GLP-1 editor's rating on five distinctive features. First: NYSE-listed parent (Teladoc Health, Inc., TDOC) — publicly-traded major mainstream telehealth platform with comprehensive corporate infrastructure (Investor Relations + Newsroom + Careers + Leadership + Trust Center + Accessibility + Compliance). Second: 12% average weight loss at 12 months published outcome data. Third: 92% of members continue GLP-1 therapy after 1 year + 98% continue to engage with Teladoc Health after 1 year — durable retention metrics. Fourth: insurance + employer + health plan sponsor primary distribution channel with self-pay options. Fifth: Teladoc Health mobile app (iOS + Android) + 15 published GLP-1 educational articles + published Trustpilot reviews link.
The bottom line
If you have insurance, employer, or health-plan-sponsor access to Teladoc Health and value NYSE-listed parent + 12-month outcome data + 92% continuation retention + comprehensive corporate infrastructure, Teladoc Health is editorially compelling. If you don't have employer access and want the cheapest possible flat-rate cash-pay compounded GLP-1, the platform may not be the best structural fit.
Start with Teladoc Health today
NYSE: TDOC. 12% / 12 mo. 92% continue. 98% engagement.
Visit Teladoc Health's Official Site →Published: June 8, 2026 · Verified: June 2026 · Spot a factual issue? Tell our editors.